Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects with Schizophrenia - SPECTRUM

Study identifier:D1443L00025

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

No

Study drug

Quetiapine Fumarate Extended- Release

Sex

All

Actual Enrollment

331

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Mar 2008
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jul 2010

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria